Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07873060
Recruiting Not applicable

Comparing 10 Hz rTMS and iTBS for Adolescent Depression

NCT07873060 · tracked via the Priya Life Science China tracker
Sponsor
Qilu Hospital of Shandong University
Phase
Not applicable
Started
2026-10-08
Last updated
2026-10-14

Condition(s) studied

Depressive Disorder, Major Depressive DisorderAdolescence

Investigational drug(s) / intervention(s)

10 Hz Repetitive Transcranial MagneticIntermittent Theta Burst Stimulation

10 Hz Repetitive Transcranial Magnetic: Non-invasive brain stimulation using a figure-of-eight coil to deliver magnetic pulses to the left dorsolateral prefrontal cortex, with individualized neuronavigation-guided coil positioning.

Intermittent Theta Burst Stimulation: Non-invasive brain stimulation using a figure-of-eight coil to deliver magnetic pulses to the left dorsolateral prefrontal cortex, with individualized neuronavigation-guided coil positioning.

Study summary

This trial compares two transcranial magnetic stimulation (TMS) protocols-10 Hz rTMS and intermittent theta burst stimulation (iTBS)-in adolescents with major depressive disorder. Eighty participants aged 11-19 years will be randomly assigned to receive either 10 Hz rTMS or iTBS over a two-week period. Clinical symptoms, cognitive function, brain imaging, and neurophysiological measures will be assessed at baseline, immediately post-treatment, and at a 1-month follow-up to evaluate both the immediate and sustained therapeutic effects and underlying mechanisms.

Eligibility

Sex
ALL
Min age
11 Years
Max age
19 Years
Healthy volunteers
No
\*\*Inclusion Criteria:\*\* * Aged 11 to 19 years * Meeting the DSM-5 criteria for MDD * Absence of current or past psychotic symptoms (e.g., auditory or visual hallucinations) * No comorbid schizophrenia, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder, panic disorder, or other severe psychiatric conditions * No contraindications to MRI or TMS, including implanted cardiac pacemakers, neurostimulators, artificial metal heart valves, intracranial aneurysm clips, cochlear implants, or other metallic implants \*\*Exclusion Criteria:\*\* * Alcohol or substance dependence * Severe or unstable medical conditions, including neurological, endocrine, and rheumatic diseases, brain disorders, traumatic brain injury or surgery, and infectious diseases * Recent receipt of rTMS or electroconvulsive therapy * High suicide risk * A history of epilepsy or unprovoked seizures * Pregnancy

Primary outcome measure(s)

  • Change in Hamilton Depression Rating Scale-24 (HAMD-24) Total Score — Baseline, Week 2, and Week 6
    Change in depressive symptom severity from baseline to Week 2 (end of treatment) and to Week 6 (1-month follow-up). The HAMD-24 is a clinician-administered scale with higher scores indicating greater depression severity.

Trial sites (1)

FacilityCityRegionStatus
Shandong Mental Health Center Jinan Shandong Recruiting

More Qilu Hospital of Shandong University trials in China

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer Active, not recruiting
Efficacy of Probiotics for OAB Patients With Anxiety Starting soon
Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score Recruiting
Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder Starting soon
The Clinical Efficacy of Immunomodulators in RA Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07873060 on ClinicalTrials.gov ↗ ← All trials in China